Celltrion Eyes U.S. As Next Target For Remicade Biosimilar Approval
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Celltrion and Japanese partner Nippon Kayaku eye the U.S. for the next approval of their biosimilar of Johnson & Johnson’s Remicade.